



Non-coding RNAs and Epigenetic Alterations in Metal-Induced Carcinogenesis

Guest Editors:

Dr. Ling-Zhi Liu

Department of Medical Oncology,
Sidney Kimmel Cancer Center,
Thomas Jefferson University,
Philadelphia, PA 19107, USA

Prof. Dr. Binghua Jiang

Department of Pathology,
Anatomy and Cell Biology, Sidney
Kimmel Cancer Center, Thomas
Jefferson University,
Philadelphia, PA 19107, USA

Deadline for manuscript
submissions:
closed (30 June 2023)

Message from the Guest Editors

Metals such as hexavalent chromium (Cr(VI)), arsenic, cadmium, and nickel are environmental carcinogens and long-term exposure to these metals is associated with the development of various types of cancer. Non-coding RNAs and epigenetic alterations have recently been demonstrated to be important in metal-induced malignant transformation, angiogenesis, and cancer development. Non-coding RNAs (ncRNAs)—especially micro-RNAs (miRNAs) and long non-coding RNAs (lncRNAs)—have been intensively investigated regarding their roles in cancer development and drug resistance. ncRNAs play important roles in metal-induced carcinogenesis and angiogenesis. This Special Issue will focus on new research findings in elucidating roles and mechanisms of ncRNAs in regulating carcinogenesis. Epigenetic regulations such as DNA methylation, RNA methylation, and histone modifications are other networks mediating carcinogenesis and cancer development. A better understanding of the complex networks of ncRNAs and epigenetic regulations would provide the opportunity to identify new biomarkers and to design new options to prevent metal-induced carcinogenesis in the future.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)